REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for REGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REGN | Board co-Chair, President and Chief Executive Officer | 73 | ["Founded the Company in 1988","Built and managed the Company for 38 years","Director, President, and Chief Executive Officer since inception","Co‑Chair of the Board since 2023","Former Chair of the Board from 1990 through 1994","Licensed physician certified in Neurology","Founded the company","Co-Chair of the Board since 2023","Previous Chair of the Board from 1990 to 1994","M.D. and Ph.D. in Pharmacology from the University of Virginia","Licensed physician","Certified in Neurology by the American Board of Psychiatry and Neurology"] | ["Technology Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 73 Director since: 1988 Board co-Chair since: 2023 Board and Committee Membership 2025 Attendance Board of Directors: 15/15 Technology Committee: 2/2 Career Highlights Founded the Company in 1988; built and managed the Company over the past 38 years together with Regeneron s founding scientist, Dr. Yancopoulos Director, President, and Chief Executive Officer of the Company since its inception Co Chair of the Board since 2023; former Chair of the Board from 1990 through 1994 Licensed physician certified in Neurology by the American Board of Psychiatry and Neurology Experience and Expertise Industry Experience Executive/Leadership Experience Science/Biotech Background Research/Academic Experience Business Strategy/ Operations Experience Financial Expertise Public Company CEO Experience Dr. Schleifer s significant industry and leadership experience, as well as his incomparable knowledge of the Company and in-depth understanding of the complex research, drug development, and business issues facing companies in the biopharmaceutical sector, led the board to conclude that Dr. Schleifer should serve as a director.